Important note: Information in this article was accurate in March 2008. The state of the art may have changed since the publication date.
Baseline inflammation and coagulation markers and changes over four weeks during a treatment interruption are strongly linked to HIV viraemia and risk of mortality
HIV Treat Bull - 2008 March-April;9(3/4):
Lewis Kuller presented further analysis from the SMART study. In summary, this international study randomised around 5,500 patients to CD4-guided treatment interruptions or continuous treatment, was stopped early because of excess death in the intermittent treatment group: with 55 vs 30 deaths over the first 16 months, most not related to opportunistic infections.
Baseline markers of inflammation and clotting as they related to total mortality, the changes of these variables, and how they related to outcome.
Two matched controls for each death prior to January 2006 when the study was stopped, were matched on a variety of variables. Logistic regression analysis was used to estimate odds ratios (OR) for mortality with adjustment for cardiovascular, HIV, co infection risk factors and other demographic factors. Baseline characteristics relating to deaths included lower CD4 counts, and a higher proportion of current smoker, diabetes, treated blood pressure and CVD, in the cases compared to the controls, all of which were adjusted for.
Markers analysed included inflammatory markers: serum amyloid A and serum amyloid P, C-reactive protein (CRP) – acute phase proteins (pentraxins), and IL-6 (a major inflammatory marker and stimulant of CRP and stimulant of release of tissue factor from smooth muscle cells in the endothelium).
The markers of coagulation that were measured were D-dimer (a measure of the breakdown of fibrogenesis that is a powerful risk factor for CVD) and prothrombin fragments 1+2 (F/1.2).
All markers have been strongly associated with cardiovascular risk in HIV-negative patients.
Kuller first reported that many of these markers were elevated at baseline and that this was significantly associated with all cause mortality. Adjusted OR (4th vs 1st quartiles) showed an almost 12-fold increased risk associated with elevated IL-6 and a 26-fold increased risk associated with increased D-dimer (both p<0.0001). CRP was associated with a 3-fold risk (p=0.03).
IL-6 and D-dimer, but not the other markers, also increased over 4 weeks in patients not on treatment, compared to those on continuous treatment (p<0.0001). Changes in both markers were strongly correlated with increases in viral load. Change from baseline to week four levels in IL-6 (OR 5.3, 95%CI 1.6-17.1; p=0.006) and D-dimer (OR 5.0. 95%CI 1.3 -18.9; p=0.02) were also strongly correlated with risk of death.
Kuller suggested that activation of coagulation and inflammation markers could impact multiple organs: the association with all cause mortality was stronger that to CVD.
This may occur as a consequence of a challenge to the endothelium. Viraemia affects vascular endothelium which increases production of tissue factor transcription, which activate the extrinsic clotting pathways. Elevated d-dimer and IL-6 clearly identified patients at highest risk of death, at a level unseen with any other marker in HIV-negative predictive biomarker studies (which report 1-2-fold increased risk. He concluded by suggesting that this opened the questions of whether this may be a useful marker to monitor in patient management.
These findings were initially presented to the IAS conference last July. [2]
References:
2008-03-10
IB080903-04
©2008. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.